CellEDIT - CRISPR-Edited U2OS Cell Line
Let us support you with a custom and high-quality engineered U2OS cell line.
Focus on your research and let us handle your CRISPR-engineered U2OS cell line.
We’ll handle the CRISPR editing of your cell line, so you can run your experiment faster and finish your project sooner. The U2OS cell line was derived in 1964 from a moderately differentiated tibial sarcoma from a 15-year-old female. The cell line displays epithelial morphology.
U2OS Cell Line Information
Organism
Human
Tissue Type
Bone
Cell Type
Epithelial
Disease
Osteosarcoma
Karyotype
Polyploid
Donor Information
Age
15
Gender
Female
Ethnicity
Unknown
U2OS Cell Line Applications
Cancer Research: As a model for studying osteosarcoma, U2OS cells help in understanding cancer biology, mechanisms of tumor development, and progression.
Drug Screening & Development: U2OS cells are used to test the efficacy and toxicity of new anticancer drugs, helping in the identification and optimization of potential therapeutic compounds.
Genetic Studies: These cells are used in gene editing and functional genomics studies to investigate the roles of specific genes and genetic pathways in cell growth and disease.
Signal Transduction Research: U2OS cells are employed to study cellular signaling pathways, particularly those related to cancer cell proliferation and survival.
Cell Cycle & Apoptosis Research: Researchers use U2OS cells to study the regulation of the cell cycle and the mechanisms of programmed cell death (apoptosis), which are crucial for understanding cancer and developing new treatments.
Related Case Studies
Leverage CellEDIT's expertise to enhance your research capabilities. Engineered U2OS cell lines provide researchers with models to gain critical insights into cancer biology, drug development, genetic functions, and cellular mechanisms. With the CellEDIT workflow and within 10 weeks, we create custom and monoclonal knockout cell lines through direct intra-nuclear injection, suited for your project needs.
Efficient on
Hard-to-transfect cells
Vector-free
direct intra-nuclear delivery
Minimized Off-Target
Immortalized Cells
Learn how
the CellEDIT workflow was used to generate 5 monoclonal HPRT knockouts in C2C12 cell line through direct intra-nuclear injection of only 51 cells.
Hard-to-Transfect Cells
Discover how
the CellEDIT workflow was used to produce 3 monoclonal HPRT1 knockouts in SK-MES-1 cell, a notoriously hard-to-transfect cell line.
Available Edits using CellEDIT Engineered Cells
Knockout
Save time in the lab by powering your research with CellEDIT. Confidently streamline your drug discovery workflow and investigate gene function with effective CRISPR knockouts.
Multiplex Editing
At CellEDIT, we provide you with multiplexed cell lines in 10 weeks. The efficiency and gentleness of our vector-free editing through intra-nuclear delivery, makes it an ideal system to perform multiplex gene editing in one go.
Related Resources
Educational
Technical
Introduction to CRISPR Knockout Gene Editing with CellEDIT
An Overview of CellEDIT' CRISPR Cell Line Development Services
CellEDIT' CRISPR Cell Line Development Workflow
CellEDIT's Engineered Cell Lines
CRISPR-Engineered MDA MB 231 Cell Line
CRISPR-Engineered A549 Cell Line
CRISPR-Edited Hek293 Cell Line
Media & Downloads
On-Demand CellEDIT's CRISPR Cell Line Engineering Webinar
CellEDIT's Application Note n*1 - Introducing the CellEDIT Workflow
CellEDIT's Application Note n*2 - Overcoming the hard-to-transfect cell line hurdle
Open Access Publication featuring CellEDIT: Antony, Justin S., Anabel Migenda Herranz, Tahereh Mohammadian Gol, Susanne Mailand, Paul Monnier, Jennifer Rottenberger, Alicia Roig‐Merino et al. " Accelerated generation of gene-engineered monoclonal CHO cell lines using FluidFM nanoinjection and CRISPR/Cas9" Biotechnology Journal 19, no. 4 (2024): 2300505.